GTPBP1 and stroke disorder: With a follow up ranging between 4.6 and 6.2 years, the comparison between the gp1 and gp3 showed a reduction in the risk of all-cause mortality (HR= 0.44, 95%CI 0.42-0.46), MI (HR= 0.76, 95%CI 0.63-0.93) and stroke (HR= 0.64, 95%CI 0.43-0.96).